$29.00
▲ +1.8% Today
as of Jul 22, 16:51 ET
Last 30 days
Recent Press Releases & News
Can Maze Therapeutics, Inc. (MAZE) Climb 120.48% to Reach the Level Wall Street Analysts Expect?
What Does the Maze Therapeutics CEO's Sale of Nearly 30,000 Shares Mean for Investors?
Maze Therapeutics Phase 2 Kidney Data Sparks Questions On Upside And Risk
Overview
52-week range
$9.83
$54
44% of range
Avg surprise (last 3)
-17.8%
Avg reaction (last 2)
-3.5%
50% positive
Latest IV / EM
92%
EM ±21.0% · $30 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue May 12, 2026 | Mar/2026 | $-0.45 | $-0.43 | -4.7% | +60.9% | +1.0% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.66 | — | — | — | — | financials |
| Tue Aug 12, 2025 | Jun/2025 | $-0.77 | $-0.79 | +2.5% | — | — | earnings |
| Wed May 14, 2025 | Mar/2025 | $-1.15 | $-0.76 | -51.3% | — | -8.1% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-10.25 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $3.22 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-13.91 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Tue Aug 11, 2026 | Jun/2026 | OTHER | -$0.76 | -$0.77 | +1.3% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $20M | — | — | $0 | — | — | $2M | $165M |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-27M | — | $-33M | $-36M | $-35M | — | $-24M | $140M |
| Net income | $-24M | — | $-30M | $-34M | $-33M | — | $-25M | $139M |
| EPS (diluted) | $-0.45 | — | $-0.66 | $-0.77 | $-1.15 | — | $-10.25 | $3.22 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $199M | $189M | $317M | $265M | $294M | $197M | $150M | $175M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $380M | $350M | $391M | $271M | $300M | $202M | — | — |
| Total assets | $420M | $397M | $422M | $304M | $333M | $241M | — | — |
| Long-term debt | $39M | — | — | — | — | — | — | — |
| Total liabilities | $78M | $42M | $43M | $41M | $41M | $44M | — | — |
| Total equity | $342M | $355M | $379M | $262M | $292M | $-311M | — | — |